Trial Profile
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms iNSITE-1
- Sponsors BIND Therapeutics
- 14 Apr 2016 Status changed from active, no longer recruiting to completed.
- 06 Apr 2016 Results published in a Bind Therapeutics media release.
- 15 Mar 2016 According to Bind Therapeutics media release, company is expecting top-line results of full 40 patients in April 2016.